Iovance Biotherapeutics (IOVA) Tops Q2 EPS by 2c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.11), $0.02 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $99.31 million versus the consensus estimate of $87.12 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Casey's General Stores (CASY) call put ratio 1.3 calls to 1 put into the quarter results
• Vishay launches 45 mm inductive encoder for industrial use